In a report by The Better India, Dr Kumar was quoted as saying, “It is something we have worked on for more than three decades, and research is still ongoing. Naturally, the process of developing any new medical device takes a long time taking into account the need for a lot of tests, addressing safety aspects and adverse effects. Nevertheless, in receiving the ‘breakthrough device’ designation from the USFDA, we feel that our work has been good enough. We hope it will also offer a breakthrough in the lives of cancer patients.”

Dr Kumar who is the Chairman and Chief Scientific Officer at the Centre for Advanced Research and Development (CARD), a research wing under the Organization de Scalene Foundation, admitted that he was ecstatic when he received the letter of approval.

The Cytotron works on the tissue engineering principles of human cells, altering how certain proteins are regulated to prevent them from multiplying and spreading in case of cancer or promote the growth of cells where required and is essentially a new way to think about repairing cellular disorders.

The Cytotron works on the tissue engineering principles of human cells, altering how certain proteins are regulated to prevent them from multiplying and spreading in case of cancer or promote the growth of cells where required and is essentially a new way to think about repairing cellular disorders.

The cell in a human body biologically multiplies anywhere up to 50 times before becoming senescent, which means it can no longer further that process. After the 50th division, there is a flag planted down, where a protein called p53, a programmed cell death protein, is expressed in old age cells. This ensures the cell doesn’t multiply any further.

This process is driven by the pro-apoptotic protein p53, which regulates apoptosis. Unfortunately, in cancer cells, this process doesn’t happen because the protein is mutated or is not expressed, as they do not receive the signal to do so. Cancer cells fail to realise when to stop multiplying and thereby progress to grow as an organ in the body. As they grow, they land up with a resource crunch. This triggers the cells’ survival instinct which begins by forming new colonies. Cancer produces a very special kind of cell, called EMT cells or cancer stem cells (CSCs), that spread to another location and then it builds up new colonies.

As long as the cancer is growing, the body’s immune system does it not attack it. On the contrary, it protects the cancer tissue. Cancer cells take advantage of this situation and conquer different organs of the body until the body cannot function normally.

“Cytotron stops the cancer tissue from multiplying and spreading to other organs. Once the tumour stops growing or spreading, what we do at Cytotron is plant the flag (protein) down, which determines that the cell is old enough to die. The moment this happens, the cell stops growing and once that happens the first reaction of the immune system is to grab the cell and throw it out. The cancer tissue is recycled, and this device also works to convert or transform the cancer stem cells into cells that don’t multiply. These are two things that happen when we treat a cancer patient with Cytotron. Depending on which stage of cancer you’re being treated at, it stops the cancer cells from spreading. The earlier you go inside the Cytotron, your cancer gets arrested at that point. Once you stop the tumour from growing and spreading, there are other ways you can manage the disease,” said Dr Kumar.

The Cytotron is a machine which has a thousand components. Generically known as rotational field quantum magnetic resonance, Cytotron produces fast radio bursts, which modulate the life systems and communicate with cells in the body. In the initial stages, the machine is being built at the CARD campus in Bengaluru. “When we need to scale up production, we may rope in another entity,” he asserted.

As per Dr Kumar, the Cytotron treatment has treated several people and is currently being used in nine countries. He stated that the Cytotron has been approved for clinical use by the Medical Devices Directive (MDD) of the European Council, the SFDA in the Middle East and the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) in South America.

In India, this machine is not yet available, although they give free treatment to as many people at their centre. From January 2020, they will start supplying these machines to hospitals and institutions.

However, addressing cancer is just one such application. The development of this machine is only one aspect of their broader research in tissue engineering, like chondrogenesis, where they grow cartilage tissue and bone tissue.

“In India, the Cytotron will cost anywhere between Rs 2.5 to Rs 3 crore,” Dr Kumar added. For patients diagnosed with cancer, he suggests that before any surgery, they should ideally be sent straight into the Cytotron so the tumour can be stopped from growing or spreading.

“In my opinion, you essentially cut down the risk of cancer spreading by going through the Cytotron. If there is a tumour that is causing pain or discomfort, you could do surgery later on. But before doing it, you must go through the Cytotron. Cancer activity stops, people feel more energetic, they put on weight, and the effects are generally good after patients undergo Cytotron treatment,” he maintained.